UBS Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
|
|||||
|
2023
Q2 | $3.98M | Buy |
|
|||||
|
2023
Q1 | $1.61M | Buy |
|
|||||
|
2022
Q4 | $94.4K | Sell |
|
|||||
|
2022
Q3 | $94K | Buy |
|
|||||
|
2022
Q2 | $78K | Buy |
|
|||||
|
2022
Q1 | $59K | Sell |
|
|||||
|
2021
Q4 | $93K | Sell |
|
|||||
|
2021
Q3 | $621K | Sell |
|
|||||
|
2021
Q2 | $1.04M | Buy |
|
|||||
|
2021
Q1 | $648K | Sell |
|
|||||
|
2020
Q4 | $1.96M | Sell |
|
|||||
|
2020
Q3 | $3.83M | Buy |
|
|||||
|
2020
Q2 | $1.75M | Buy |
|
|||||
|
2020
Q1 | $456K | Sell |
|
|||||
|
2019
Q4 | $3.18M | Buy |
|
|||||
|
2019
Q3 | $479K | Sell |
|
|||||
|
2019
Q2 | $636K | Sell |
|
|||||
|
2019
Q1 | $2.41M | Buy |
|
|||||
|
2018
Q4 | $1.54M | Buy |
|
|||||
|
2018
Q3 | $2.17M | Sell |
|
|||||
|
2018
Q2 | $1.23M | Buy |
|
|||||
|
2018
Q1 | $409K | Buy |
|
|||||
|
2017
Q4 | $99K | Buy |
|
|||||
|
2017
Q3 | $73K | Sell |
|
|||||
|
2017
Q2 | $105K | Buy |
|
|||||
|
2017
Q1 | $27K | Sell |
|
|||||
|
2016
Q4 | $54K | Buy |
|
|||||
|
2016
Q3 | – | Sell |
|
|||||
|
2016
Q2 | $40K | Buy |
|